Form 4: Ionis Pharma EVP Sells 8,000 Shares Under 10b5-1 Plan
Insider Transaction Disclosure
Ionis Pharmaceuticals' EVP Brian Birchler reported the sale of 8,000 shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Brian Birchler, Executive Vice President of Corporate and Development Operations at Ionis Pharmaceuticals Inc. (IONS), reported the sale of 8,000 shares of common stock.
- The transaction occurred on November 6, 2025, at a weighted average price of $76.1724 per share.
- The shares were sold in multiple transactions with prices ranging from $76.00 to $76.32.
- This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Birchler on August 12, 2024.
- Following this transaction, Mr. Birchler beneficially owns 48,826 shares of Ionis Pharmaceuticals common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine disclosure of an insider stock sale executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new company-specific news or performance.
Future Outlook
This filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
Insider transactions, particularly those executed under pre-arranged 10b5-1 plans, are common in the biotechnology and pharmaceutical industries as a means for executives to manage personal finances and diversify holdings while adhering to insider trading regulations. This specific transaction does not inherently indicate a shift in company strategy or performance.
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in an executive's direct holdings, which is a routine event under a 10b5-1 plan and is unlikely to have a significant impact on shareholder confidence or the company's operational direction.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date Rule 10b5-1 Trading Plan was adopted by Brian Birchler. |
| 11/06/2025 | Date of transaction (sale of common stock). |
| 11/07/2025 | Date the Form 4 was signed. |
Keywords
Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.